Table 3.

Effects of proteins containing jumonji domain on drug resistance

Enzyme	Cancer type	Drug	Effect or mechanism	Reference
KDM2A	hepatoma	Sorafenib	Increase the formation of tumor stem cells	281
KDM2B	glioblastoma	Chemotherapeutic agents	Induce the expression of p21CIP1/WAF1 and increase the apoptosis	282
KDM3A	breast cancer	Cisplatin	Activate SOX2 and inhibit p53 activity to regulate BCL-2 expression	287
JMJD1C	ESCC	Paclitaxel	Inhibit cell apoptosis rate and reduce metastasis	290
KDM4A	castrated resistant prostate cancer	Enzalutamide	Regulate the stability of USP14-AR and prevent AR degradation	295
KDM4B	prostate cancer	Enzalutamide	Increase the transcription of C-MyC	297
KDM4C	acute myeloid leukemia	Cytarabine	Increase the expression of MALAT1 and activate cyclin CCND2	299
	gastric cancer	Cisplatin	Activate ALDH1A3 transcription and maintain stemness	301
KDM5A	glioblastoma	Temozolomide	Promote resistance and inhibit apoptosis	304
	ER (+) breast tumor	Tamoxifen	Activate IGF1R and ErbB signaling, thereby causing the activation of PI3K/AKT/mTOR pathway	305
	lung adenocarcinoma	Paclitaxel	Increase the expression of P-gp; promote EMT	307
KDM5B	gastric cancer	Cisplatin	Recruit XRCC1 and inhibit cell apoptosis	309
KDM5C	CRPC; nasopharyngeal carcinoma; gastric cancer	Chemotherapeutic agents	Inhibit apoptosis and promote cell proliferation and resistance	315,316
	colorectal cancer; ccRCC	Oxaliplatin;	Promote cell growth while its knockdown promote resistance	318,319
KDM5D	prostate cancer	Docetaxel	Regulate androgen transcription; inhibit MYBL2 expression	321,322
KDM6A	AML	AraC; imatinib	Increase ENT1; upregulate TRKA expression through YY1	325,326
KDM6B	neuroblastoma	Palbociclib	Activate the CDK4/6-pRB-E2F pathway	335
KDM7A	bladder cancer	Cisplatin	Regulate AR transcription activity	336
PHF8	breast cancer	Trastuzumab	Interact with HER2 and regulate the expression of IL6	338
JARID2	non-small cell lung cancer	Cisplatin	Increase the expression of Notch1 and regulate cell stemness	339